家族性高コレステロール血症における妊娠の結果:レジストリベースの研究
Ieva Toleikyte1, Kjetil Retterstøl, Trond Paul Leren
1Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway.
Circulation
|September 14, 2011
まとめ
ファミリアル高コレステロール血症 (FH) の女性は,早産,低出生体重,または先天性不形成のリスクの増加に直面しません. この研究では,一般の人々と比較して有意な差異は見つかりませんでした.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 生殖器保健は,生殖器の健康についてです.
- 臨床流行病学 臨床流行病学とは
背景:
- 家族性高コレステロール血症 (FH) は,女性における心血管疾患のリスクを大幅に増加させる.
- FHが妊娠と出産の結果に与える影響は,まだほとんど調査されていない.
- これらのリスクを理解することは,生殖年齢の女性のFHの管理に不可欠です.
研究 の 目的:
- ヘテロジゴト性FHと不良妊娠結果の関連性を調査する.
- FHの女性における早産,低出生体重,先天性不形成のリスクを一般の人々と比較するために.
- FHの妊婦の臨床ガイドラインを参考にすること.
主な方法:
- 医療遺伝学研究室とノルウェーの医療出生登録 (1967年−2006年) のリンクされたデータを活用した.
- ヘテロジゴス型FHの女性1093人,一般人口の約200万人の出産を含む.
- 胎児の早産,低出生体重,先天性変形などの出産結果を分析した.
主要な成果:
- FH女性における早産,低出生体重,先天性不形成の頻度はそれぞれ6.8%,5.0%,3.3%でした.
- 一般人口の対応する頻度は6.2%,5.2%,3.2%でした.
- FHの女性における有害な結果に対する確率比は非有意であった (早産: 1.11,低出生体重: 0.96,変形: 1.09).
結論:
- FHの女性は,早産,低出生体重の乳児,または先天性不形成の統計的に有意なリスクを示さない.
- 発見は,FHがこれらの特定の妊娠および出産の結果に悪影響を及ぼさない可能性があることを示唆しています.
- 検出されていない潜在的なバイアスを完全に排除することはできませんので,慎重に解釈する必要があります.
関連する概念動画
Lipid-derived Compounds in the Human Body
5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


